Compare Bristol-Myers Squibb Co (BMY) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nutrien Ltd — how do they compare? Bristol-Myers Squibb Co trades at $58.52 (market cap $116.30B), while Nutrien Ltd trades at $67.18 (market cap $32.62B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.6× Nutrien Ltd's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NTR | |
|---|---|---|
Market Cap | $116.30B | $32.62B |
Sector | Health | Basic Materials |
52-Week High | $62.37 | $83.94 |
52-Week Low | $42.60 | $53.64 |
Enterprise Value | $152.24B | $45.79B |
Dividend Yield | 4.42% | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Nutrien (NTR) trades at $67.60, up 3.32% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 13.77 and net income margin of 8.58%. Recent earnings beat expectations in Q1 2026, and analyst consensus is strongly positive with a $79.50 price target. The company maintains solid cash flow from operations at $4.01 billion despite recent net cash outflows.
NTR presents a compelling value opportunity with reasonable valuation metrics and strong analyst support. Key risks include volatile fertilizer prices and global agricultural demand fluctuations. The upcoming Q2 2026 earnings report with expected EPS of $2.89 represents a significant near-term catalyst for price movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
